On December 5, 1996, Sucampo Pharmaceuticals, Inc. was incorporated in the state of Delaware.
Sucampo is headquartered at805 King Farm Boulevard, Suite 550, Rockville, Maryland 20850.
Sucampo’s initial public offering occurred on August 2, 2007, with 3,750,000 class A common stock shares sold at a price of $11.50 per share.
As of March 31, 2015, Sucampo employed approximately 84 employees in three continents.
American Stock Transfer & Trust LLC, 6201 15th Avenue, Brooklyn, NY 11219.
Ernst & Young, LLP
Sucampo runs on a calendar year with the fiscal year ending on December 31.
Our class A common stock has been approved for quotation on the NASDAQ Global Market under the symbol “SCMP.”
Sucampo does not currently pay a dividend.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.